Amarin Corp Plc (AMRN)

[HDGabor]

C-

a.) I am not sure that all "condition" (are not unusual, far-fetched, impractical, occasional, aberrant, or experimental) have to be met.

b.)
(i) MARINE indication for less than 12 weeks / for more than 12 weeks
(ii) MARINE indication / R-IT indication

As MARINE indication for less than 12 weeks was judged as substantial (are not unusual, far-fetched, impractical, occasional, aberrant, or experimental) it is more likely the FULL (less than and at least 12 weeks) MARINE indication will be judged the same way.

c.) VHTG indication, use is independent from Amarin / Vascepa. It existed before Vascepa ... are not unusual, far-fetched, impractical, occasional, aberrant, or experimental

d.) Meanwhile off-label use (pre Dec 2019 or pre Sep 2018) existed - more likely the majority was MARINE use (especially before Sep 2018). It is still (Q1 2020) more than 10%.

To me there's a very good case for induced infringement

Non-infringing use (exist or does not) is irrelevant for inducement. It matters for contributory infringement.

Best,
G